GH658 / Genhouse Bio - LARVOL DELTA

Discovery of GH658, a novel tead allosteric inhibitor as a cancer therapy (AACR 2023) - "More importantly, GH658 displayed significant in vivo effect on drug tolerant persistent cancer cells and drug resistance against inhibitors targeting EGFR‒RAS signaling pathways in combination studies. In summary, with potent in vitro and in vivo efficacy of targeting YAP/TAZ‒TEAD transcriptional complex, GH658 not only showed consistent monotherapy activity in selected cancer models, but also demonstrated significant synergistic effects in diverse drug combination studies."

Lung Cancer • Mesothelioma • Oncology • Solid Tumor